Christopher Peetz, chief executive officer of Mirum Pharmaceuticals (NASDAQ: MIRM), completed a sale of 9,108 common shares on February 2, 2026, at a per-share price of $103.3035. The transaction produced proceeds of $940,888 and was carried out to satisfy tax withholding requirements associated with the vesting of restricted stock units.
Following the disposition, Peetz retains direct ownership of 160,294 Mirum shares and holds an additional 187,500 shares indirectly through The Peetz Family Trust. The sale comes as the biopharmaceutical company trades near its 52-week high of $105.64, having delivered approximately 110% returns over the past 12 months and carrying a market value of roughly $6.3 billion.
Although Mirum has not yet reached profitability, available InvestingPro data indicate a strong liquidity position, with a reported current ratio of 3.31. That ratio signals that the company’s liquid assets exceed its short-term liabilities by a substantial margin.
Mirum’s operational updates have been positive in recent disclosures. The company reported preliminary unaudited net product sales for 2025 of about $520 million, a figure that surpassed its prior guidance. For 2026, Mirum has issued guidance for global net product sales in the range of $630 million to $650 million, representing potential year-over-year growth up to 25%.
Strategic expansion also factored into the company’s recent activity. Mirum completed its acquisition of Bluejay Therapeutics, securing brelovitug, a late-stage monoclonal antibody therapy aimed at chronic hepatitis delta virus. Regulatory designations for brelovitug include Breakthrough Therapy status from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency.
Analyst sentiment reflected optimism across a number of firms. A consensus analyst recommendation stands at 1.2 on a 1-to-5 scale, where 1 denotes a strong buy. H.C. Wainwright raised its price target to $130 while keeping a Buy rating and pointed to the potential of volixibat for chronic liver diseases. Citizens reiterated a Market Outperform rating and a $140 price target, referencing robust 2025 sales for Livmarli and related bile acid portfolio products. Baird lifted its target to $95 from $88 after sales exceeded expectations.
InvestingPro subscribers are offered more comprehensive analysis, including a Pro Research Report that compiles additional insights and 14 ProTips on Mirum’s financials and outlook.
Bottom line: The insider sale by Mirum’s CEO was a targeted transaction to meet tax obligations tied to RSU vesting. It coincides with strong sales momentum, upward analyst revisions, completion of an acquisition that added a late-stage therapy to the pipeline, and a firm liquidity position despite the company not being profitable yet.